Advertisement
U.S. markets closed

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.57+0.08 (+1.46%)
At close: 04:00PM EST
5.40 -0.17 (-3.05%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close5.49
Open5.61
Bid5.55 x 1200
Ask5.70 x 800
Day's Range5.40 - 5.95
52 Week Range1.57 - 6.67
Volume1,796,529
Avg. Volume1,087,615
Market Cap435.986M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Annexon, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

    BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a corporate panel discussion focused on Ophthalmology, at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:10 p.m. ET in Boston, MA.

  • GlobeNewswire

    Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

    Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, Professor Emeritus of Johns Hopkins University School of Medicine BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for peop

  • GlobeNewswire

    Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-